● Recruiting

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Condition: Nasopharyngeal Carcinoma · Sponsor: Ming-Yuan Chen

PhasePhase 3

Planned participants346

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediate-stage nasopharyngeal carcinoma patients.

This description comes directly from the study's public registry record.

Talk to the study team

Ming-Yuan Chen, MD,PhD · +86-20-87343361 · chenmy@sysucc.org.cn

Rui You, MD,PhD · +86-13580439820 · your5@mail.sysu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (15)

Anhui Provincial Cancer Hospital	Hefei, Anhui, China	Recruiting
Fujian Cancer Hospital	Fuzhou, Fujian, China	Recruiting
Sun Yat-sen University cancer center	Guangzhou, Guangdong, China	Recruiting
the Affiliated Cancer Hospital of Guangzhou Medical University	Guangzhou, Guangdong, China	Recruiting
Cancer Hospital of Shantou University Medical College	Shantou, Guangdong, China	Recruiting
Zhongshan City People's Hospital	Zhongshan, Guangdong, China	Recruiting
The Fifth Affiliated Hospital of Sun Yat-sen University	Zhuhai, Guangdong, China	Recruiting
Guangxi Medical University Cancer Hospital	Nanning, Guangxi, China	Recruiting
Wuzhou Red Cross Hospital	Wuzhou, Guangxi, China	Recruiting
Central South University Cancer Hospital,	Changsha, Hunan, China	Recruiting
Xiangya Hospital of Central South University	Changsha, Hunan, China	Recruiting
West China Hospital, Sichuan University	Chengdu, Sichuan, China	Recruiting

+ 3 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07328854